If you have struggled with weight loss and tried different diets with only limited success you might be wondering if a GLP-1 agonist such as Semaglutide (Wegovy/Ozempic) or Tirzepatide (Zepboubd/Mounjaro) could be right for you? Maybe you have not tried these medications due to fear of muscle loss, getting “Ozempic face”, dependence on the medications, preference to maintain a healthy weight organically or simply due to cost.
—
What Are GLP-1 Agonists?
Glucagon-like peptide-1 (GLP-1) is a hormone naturally produced in cells of the intestine. GLP-1 agonists are innovative medications that mimic the body’s natural hormone but last much longer than the natural hormone and thus can help manage weight and improve metabolic health. These drugs were originally developed for diabetes management but have been found to also lead to significant weight loss.
—
How do GLP-1 Agonists promote weight reduction?
- Appetite Suppression: They act on specific areas of the brain, particularly the hypothalamus, to reduce hunger signals and increase feelings of fullness or satiety. This leads to decreased overall food intake [1, 2].
- Reduced Cravings: These medications can also influence the brain’s reward system, potentially reducing cravings for high-calorie foods [1].
- Delayed Gastric Emptying: GLP-1 agonists slow the rate at which food leaves the stomach. This prolonged stomach emptying contributes to feeling fuller for longer after meals, which can lead to reduced calorie consumption [1, 3].
—
Benefits of GLP-1 Agonists other than weight loss
Blood Sugar Control: GLP-1 agonists help regulate blood sugar levels.
- They stimulate the pancreas to release insulin when blood sugar is high. Insulin is a hormone that lowers blood sugar by increasing uptake of glucose into cells [3, 4].
- They slow gastric emptying, which delays glucose absorption into the bloodstream, preventing rapid blood sugar spikes after meals [3, 4].
- They reduce glucagon secretion from the pancreas. Glucagon is a hormone that increases blood sugar. This combined action helps maintain stable blood sugar levels [3, 4].
Heart Health: GLP-1 agonists have significant cardiovascular benefits.
- They exert direct protective effects on blood vessels, reducing inflammation and improving endothelial function [5, 6].
- They can contribute to lower blood pressure and improved cholesterol levels, both critical for cardiovascular health [5, 6].
- Clinical trials have demonstrated that GLP-1 agonists can reduce the risk of major adverse cardiovascular events such as heart attack, stroke, and cardiovascular death [5, 7].
Kidney Protection: These medications offer protective effects on kidney function.
- GLP-1 agonists have shown direct benefits in slowing the progression of kidney disease, independent of their effects on blood sugar or weight [8, 9].
- They can reduce albuminuria (protein in the urine), which is a marker of kidney damage [8, 10].
- They exhibit anti-inflammatory properties within the kidneys, helping to preserve kidney structure and function [9, 10].
Liver Health: GLP-1 agonists can improve liver health, particularly concerning fatty liver disease.
- They can reduce hepatic steatosis (fat accumulation in the liver), which is a characteristic of non-alcoholic fatty liver disease (NAFLD). This can prevent or mitigate liver damage [11, 12].
- Studies indicate they can improve liver enzyme levels, which are indicators of liver health [12, 13].
Brain Health: Emerging research suggests GLP-1 agonists may have beneficial effects on brain health, including in areas of addiction and cognitive function.
- Addiction: GLP-1 receptors are present in brain regions involved in reward and motivation [14, 15]. By modulating the brain’s dopamine reward system, GLP-1 agonists show promise in reducing cravings and compulsive behaviors associated with various substance use disorders, including alcohol, nicotine, and potentially opioids and stimulants [14, 16, 17]. This may be due to their ability to normalize dopamine signaling, which can be altered in addiction [15].
- Cognitive Decline: GLP-1 agonists exhibit neuroprotective properties. They can cross the blood-brain barrier and are expressed in brain regions vital for memory and learning, like the hippocampus [18, 19]. Their proposed mechanisms include:
- Reducing neuroinflammation: They can decrease inflammation in the brain, which is a factor in neurodegenerative diseases [19, 20].
- Improving brain energy metabolism: They may enhance glucose utilization and insulin sensitivity in brain cells, which can be impaired in conditions like Alzheimer’s disease [19, 21].
- Promoting neurogenesis and synaptic plasticity: They may support the growth of new brain cells and strengthen connections between neurons, essential for cognitive function [18, 19].
- Reducing pathological protein aggregates: Preclinical studies suggest they can help reduce the accumulation of abnormal proteins (like amyloid-beta and tau tangles) associated with Alzheimer’s and Parkinson’s diseases [19, 22].
- Observational studies indicate a potential reduced risk of developing dementia, including Alzheimer’s, in patients using GLP-1 agonists [16, 23].
—
Why Partner with Dr. Tracee Metcalfe and The Synergy Clinic?
Choosing the right weight loss therapy is a personal decision that should be based on your unique health background and goals. Dr. Metcalfe believes that GLP-1 agonists are powerful tools to jump start weight loss and metabolic health, but the ultimate goal is to help you achieve and maintain your ideal body weight without lifelong need for medications. Dr. Tracee Metcalfe uses her comprehensive training to:
- Provide comprehensive laboratory analysis at the start and periodically
- Provide body composition analysis with InBody scanning
- Discussion of GLP-1 agonist options and other therapies
- Tailored recommendations for nutrition, activity, and medication use
Precision Body Composition Analysis with InBody
At The Synergy Clinic, we utilize the advanced InBody scan to get a detailed picture of your body composition. This technology allows us to:
- Measure body fat percentage, muscle mass, and visceral fat
- Track changes over time to ensure fat loss while preserving muscle
- Tailor your nutrition, medications, and exercise recommendations for optimal results
—
The Synergy Clinic Difference
When you partner with Dr. Tracee Metcalfe at The Synergy Clinic, you receive:
- Medical expertise in weight management
- Individualized, science-backed guidance, no “one size fits all” protocols
- Advanced technology for tracking progress
- A holistic and supportive approach every step of the way
—
Common Side Effects
By starting patients on a low dose and increasing it gradually most of these side effects can be minimized. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can also help manage digestive discomfort.
- Nausea: This is the most common side effect.
- Diarrhea
- Vomiting
- Constipation
- Abdominal Pain
- Bloating, Belching, and Gas
- Acid Reflux or Heartburn
- Fatigue
- Headache or Dizziness
—
Less Common Side Effects
- Pancreatitis
- Gallbladder Problems
- Kidney Problems: In rare cases, severe vomiting and diarrhea can lead to dehydration, which can cause or worsen kidney issues.
- Increased Heart Rate: Some individuals may experience a persistent increase in their resting heart rate.
- Ileus / bowel obstruction
- Serious Allergic Reactions: Swelling of the face, lips, tongue, or throat, problems breathing or swallowing, severe rash.
- Changes in Vision: Particularly in people with type 2 diabetes.
- Hypoglycemia (Low Blood Sugar): The risk is low when GLP-1s are used alone but increases significantly when they are combined with other diabetes medications like insulin or sulfonylureas.
—
Contraindications
- Personal or Family History of Medullary Thyroid Cancer or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
- Previous Serious Hypersensitivity Reaction: Patients who have had a severe allergic reaction (e.g., anaphylaxis or angioedema) to the specific GLP-1 agonist or any of its ingredients should not take it.
- History of Pancreatitis: Relative contraindication
- Type 1 Diabetes
- Gastroparesis
- Pregnancy and Breastfeeding
- Diabetic Retinopathy
—
If you’re ready to explore whether a GLP-1 agonist or other medication is right for you, schedule your consultation and InBody scan with us today. Let’s work together to achieve your best health—safely and sustainably.
—
—
References
[1] Eisenberg, M. J., & Eisenberg, C. E. (2025). Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine, 138(6), 934-940.
[2] Salvador, J. (2025). GLP-1-based medications: Mechanisms involved in obesity treatment. Medicina Clínica (English Edition), 165(1), 107035.
[3] Drucker, D. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101131. [4] Baggio, L. L., & Drucker, D. J. (2014). Regulation of Glucose Homeostasis by GLP-1. Physiological Reviews, 94(4), 1279-1327.
[5] Kallash, M., & Frishman, W. H. (2025). The Cardiovascular Benefits of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists. Cardiology in Review. Ahead of print.
[6] Vujacic, M., Marinkovic, M., Radosavljevic, J., et al. (2023). The benefits of GLP1 receptors in cardiovascular diseases. Postgraduate Medical Journal, 100(1179), 35-42.
[7] Sun, H., Yuan, S., & Li, L. (2025). Therapeutic Potential of GLP-1 Receptor Agonists in Diabetes and Cardiovascular Disease: Mechanisms and Clinical Implications. Cardiovascular Drugs and Therapy. Ahead of print.
[8] Alicic, R. Z., & Cherney, D. Z. I. (2022). GLP-1 receptor agonists in diabetic kidney disease: current evidence and future directions. Kidney Research and Clinical Practice, 41(1), 3–14.
[9] Sharma, M., & George, J. (2023). Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: A review of their kidney and heart protection. Journal of Clinical and Translational Endocrinology, 32, 100346.
[10] Vallon, V., & Bakris, G. L. (2022). Mechanisms of Cardiorenal Protection of Glucagon-Like Peptide-1 Receptor Agonists. Endocrinology and Metabolism Clinics of North America, 51(2), 273-289.
[11] Xu, E., Ye, E., Han, Y., et al. (2012). GLP-1 Receptor Agonist and Non-Alcoholic Fatty Liver Disease. International Journal of Endocrinology, 2012, 974164.
[12] Mantovani, A., & Targher, G. (2023). Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. The Lancet Gastroenterology & Hepatology, 8(2), 179-191.
[13] Singh, S., & Bajaj, V. (2024). The role of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatohepatitis. Diabetes, Obesity and Metabolism, 26(6), 2001-2016.
[14] Carstens, S. (2025). Can GLP-1 medications impact substance use? Penn Medicine Physicians’ Hub. Retrieved from https://www.pennmedicine.org/physicians-hub/physician-article/can-glp-1-medications-impact-substance-use
[15] Lembke, A. (2025). Five things to know about GLP-1s and addiction. Stanford Medicine. Retrieved from https://med.stanford.edu/news/insights/2025/04/ozempic-addiction-glp-1s-mounjaro-lembke.html
[16] AAMC. (2025). Could popular weight-loss drugs help treat addiction and dementia? AAMC News. Retrieved from https://www.aamc.org/news/could-popular-weight-loss-drugs-help-treat-addiction-and-dementia
[17] News-Medical.net. (2025). Are GLP-1 Drugs the Future of Alcohol Addiction Treatment? News-Medical.net. Retrieved from https://www.news-medical.net/health/Are-GLP-1-Drugs-the-Future-of-Alcohol-Addiction-Treatment.aspx
[18] Reich, N., & Hölscher, C. (2022). The neuroprotective effects of glucagon-like peptide 1 in Alzheimer’s and Parkinson’s disease: An in-depth review. Frontiers in Neuroscience, 16, 970925.
[19] Gejl, M., & Egefjord, L. (2025). Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders. Journal of Neurology, Neurosurgery & Psychiatry. Ahead of print.
[20] Guan, X., Liu, R., & Wu, F. (2025). Research on the effects of GLP-1 receptor agonists in treating cognitive dysfunction and gait disorders in elderly patients with diabetes. Frontiers in Pharmacology. Ahead of print.
[21] MDPI. (2025). Exploring the Role of GLP-1 Receptor Agonists in Alzheimer’s Disease: A Review of Preclinical and Clinical Evidence. MDPI. Retrieved from https://www.mdpi.com/2813-2564/4/1/2
[22] Alzheimer’s Drug Discovery Foundation. (n.d.). GLP-1 Receptor Agonists. Retrieved from https://www.alzdiscovery.org/uploads/cognitive_vitality_media/GLP-1-Receptor-Agonists-Cognitive-Vitality-For-Researchers.pdf
[23] PMC. (2025). Effect and mechanism of GLP-1 on cognitive function in diabetes mellitus. PubMed Central. Retrieved from https://pmc.ncbi.nlm.nih.gov/articles/PMC11959055/
.
Leave a Reply